Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: A review of the literature
Authors:
- Kimberly A. BoswellKBKimberly A. Boswell
- Xufang WangXWXufang Wang
- Manasee V. ShahMSManasee V. Shah
- Matti S. AaproMAMatti S. Aapro
Open Access
- 1 December 2012
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 21 (6) , 701-706
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- 1st International consensus guidelines for advanced breast cancer (ABC 1)The Breast, 2012
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtypeBreast Cancer Research, 2007
- Assessing the economic burden of breast cancer in a US managed care populationBreast Cancer Research and Treatment, 2007
- Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor StatusJNCI: Journal of the National Cancer Institute, 2007
- Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. womenBreast Cancer Research, 2007
- Psychological morbidity and quality of life in women with advanced breast cancer: A cross-sectional surveyPalliative and Supportive Care, 2006
- Not Working 3 Years After Breast Cancer: Predictors in a Population-Based StudyJournal of Clinical Oncology, 2005
- Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregiversCanadian Medical Association Journal, 2004
- Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast CancerValue in Health, 2000